92 results on '"Prostatic tumor"'
Search Results
2. Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells.
- Author
-
Beauchemin, Nicole, Kunath, Tilo, Robitaille, Julie, Chow, Bernard, Turbide, Claire, Daniels, Eugene, and Veillette, André
- Subjects
GLYCOPROTEINS ,BILE salts ,COLON cancer ,PROTEIN-tyrosine phosphatase - Abstract
Biliary glycoprotein (Bgp) is a member of the immunoglobulin superfamily and the carcinoembryonic antigen family. Previous studies have shown that Bgp functions as an intercellular adhesion molecule and a canalicular bile salt transporter. Moreover, we and others demonstrated that Bgp can inhibit colonic and prostatic tumor cell growth in vivo, through a mechanism which depends on sequences present in its cytoplasmic domain. In this study, we have examined the possibility that the cytoplasmic domain of Bgp can interact with signal transduction molecules. We showed that tyrosine phosphorylated Bgp, expressed in mouse colon carcinoma CT51 cells, could reversibly associate with protein tyrosine phosphatase SHP-1. Mutation of either of two tyrosine residues present in the cytoplasmic domain of Bgp abrogated SHP-1 binding, suggesting that this association was mediated by both tyrosine residues. Similarly, we noted that either of the two SH2 domains of SHP-1 could bind tyrosine phosphorylated Bgp in vitro. It is therefore conceivable that some of the functions of Bgp are mediated through its ability to induce intracellular protein tyrosine dephosphorylation. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
3. Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis
- Author
-
He, Yongfeng, Mi, Jiaqi, Olson, Adam, Aldahl, Joseph, Hooker, Erika, Yu, Eun-Jeong, Le, Vien, Lee, Dong-Hoon, Kim, Won Kyung, Robins, Diane M., Geradts, Joseph, and Sun, Zijie
- Published
- 2020
- Full Text
- View/download PDF
4. Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy.
- Author
-
DiNatale A, Kaur R, Qian C, Zhang J, Marchioli M, Ipe D, Castelli M, McNair CM, Kumar G, Meucci O, and Fatatis A
- Subjects
- Humans, Animals, Mice, Female, Male, Cell Line, Tumor, Prostatic Neoplasms pathology, Prostatic Neoplasms drug therapy, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, Docetaxel pharmacology, Neoplasm Metastasis, Nanog Homeobox Protein genetics, Nanog Homeobox Protein metabolism, Gene Expression Regulation, Neoplastic drug effects, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, CX3C Chemokine Receptor 1 genetics, CX3C Chemokine Receptor 1 metabolism, Drug Resistance, Neoplasm genetics, Neoplastic Stem Cells pathology, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells drug effects, Breast Neoplasms pathology, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms metabolism, Octamer Transcription Factor-3 genetics, Octamer Transcription Factor-3 metabolism
- Abstract
Metastasis-initiating cells (MICs) display stem cell-like features, cause metastatic recurrences and defy chemotherapy, which leads to patients' demise. Here we show that prostate and breast cancer patients harbor contingents of tumor cells with high expression of CX3CR1, OCT4a (POU5F1), and NANOG. Impairing CX3CR1 expression or signaling hampered the formation of tumor spheroids by cell lines from which we isolated small subsets co-expressing CX3CR1 and stemness-related markers, similarly to patients' tumors. These rare CX3CR1
High cells show transcriptomic profiles enriched in pathways that regulate pluripotency and endowed with metastasis-initiating behavior in murine models. Cancer cells lacking these features (CX3CR1Low ) were capable of re-acquiring CX3CR1-associated features over time, implying that MICs can continuously emerge from non-stem cancer cells. CX3CR1 expression also conferred resistance to docetaxel, and prolonged treatment with docetaxel selected CX3CR1High phenotypes with de-enriched transcriptomic profiles for apoptotic pathways. These findings nominate CX3CR1 as a novel marker of stem-like tumor cells and provide conceptual ground for future development of approaches targeting CX3CR1 signaling and (re)expression as therapeutic means to prevent or contain metastasis initiation., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2022
- Full Text
- View/download PDF
5. Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition
- Author
-
Zhang, K, Zhao, H, Ji, Z, Zhang, C, Zhou, P, Wang, L, Chen, Q, Wang, J, Zhang, P, Chen, Z, Zhu, H H, and Gao, W-Q
- Published
- 2016
- Full Text
- View/download PDF
6. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2.
- Author
-
Kroiss, A, Vincent, S, Decaussin-Petrucci, M, Meugnier, E, Viallet, J, Ruffion, A, Chalmel, F, Samarut, J, and Allioli, N
- Subjects
MICRORNA ,CANCER cells ,PROSTATE cancer ,ANDROGEN receptors ,BIOMARKERS - Abstract
Androgen signaling, via the androgen receptor (AR), is crucial in mediating prostate cancer (PCa) initiation and progression. Identifying new downstream effectors of the androgens/AR pathway will allow a better understanding of these mechanisms and could reveal novel biomarkers and/or therapeutic agents to improve the rate of patient survival. We compared the microRNA expression profiles in androgen-sensitive LNCaP cells stimulated or not with 1 nM R1881 by performing a high-throughput reverse transcriptase-quantitative PCR and found that miR-135a was upregulated. After androgen stimulation, we showed that AR directly activates the transcription of miR-135a2 gene by binding to an androgen response element in the promoter region. Our findings identify miR-135a as a novel effector in androgens/AR signaling. Using xenograft experiments in chick embryos and adult male mice, we showed that miR-135a overexpression decreases in vivo invasion abilities of prostate PC-3 cells. Through in vitro wound-healing migration and invasion assays, we demonstrated that this effect is mediated through downregulating ROCK1 and ROCK2 expression, two genes that we characterized as miR-135a direct target genes. In human surgical samples from prostatectomy, we observed that miR-135a expression was lower in tumoral compared with paired adjacent normal tissues, mainly in tumors classified with a high Gleason score (⩾8). Moreover, miR-135a expression is lower in invasive tumors, showing extraprostatic extension, as compared with intraprostatic localized tumors. In tumor relative to normal glands, we also showed a more frequently higher ROCK1 protein expression determined using a semi-quantitative immunohistochemistry analysis. Therefore, in tumor cells, the lower miR-135a expression could lead to a higher ROCK1 protein expression, which could explain their invasion abilities. The highlighted relationship between miR-135a expression level and the degree of disease aggressiveness suggests that miR-135a may be considered as a prognostic marker in human PCa. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. δ-Catenin, a Wnt/β-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming.
- Author
-
Nopparat, J, Zhang, J, Lu, J-P, Chen, Y-H, Zheng, D, Neufer, P D, Fan, J M, Hong, H, Boykin, C, and Lu, Q
- Subjects
CATENINS ,WNT proteins ,MUTAGENESIS ,CANCER cell adaptation ,GENETIC mutation ,CELL communication ,CELLULAR signal transduction - Abstract
Mutations of Wnt/β-catenin signaling pathway has essential roles in development and cancer. Although β-catenin and adenomatous polyposis coli (APC) gene mutations are well established and are known to drive tumorigenesis, discoveries of mutations in other components of the pathway lagged, which hinders the understanding of cancer mechanisms. Here we report that δ-catenin (gene designation: CTNND2), a primarily neural member of the β-catenin superfamily that promotes canonical Wnt/β-catenin/LEF-1-mediated transcription, displays exonic mutations in human prostate cancer and promotes cancer cell survival adaptation and metabolic reprogramming. When overexpressed in cells derived from prostate tumor xenografts, δ-catenin gene invariably gives rise to mutations, leading to sequence disruptions predicting functional alterations. Ectopic δ-catenin gene integrating into host chromosomes is locus nonselective. δ-Catenin mutations promote tumor development in mouse prostate with probasin promoter (ARR
2 PB)-driven, prostate-specific expression of Myc oncogene, whereas mutant cells empower survival advantage upon overgrowth and glucose deprivation. Reprogramming energy utilization accompanies the downregulation of glucose transporter-1 and poly (ADP-ribose) polymerase cleavage while preserving tumor type 2 pyruvate kinase expression. δ-Catenin mutations increase β-catenin translocation to the nucleus and hypoxia-inducible factor 1α (HIF-1α) expression. Therefore, introducing δ-catenin mutations is an important milestone in prostate cancer metabolic adaptation by modulating β-catenin and HIF-1α signaling under glucose shortage to amplify its tumor-promoting potential. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
8. A reciprocal role of prostate cancer on stromal DNA damage.
- Author
-
Banerjee, J, Mishra, R, Li, X, Jackson, R S, Sharma, A, and Bhowmick, N A
- Subjects
PROSTATE cancer & genetics ,DNA damage ,CANCER invasiveness ,SOMATIC mutation ,TRANSFORMING growth factor receptors ,FIBROBLASTS ,EPIGENETICS ,DNA repair - Abstract
DNA damage found in prostate cancer-associated fibroblasts (CAF) promotes tumor progression. In the absence of somatic mutations in CAF, epigenetic changes dictate how stromal coevolution is mediated in tumors. Seventy percent of prostate cancer patients lose expression of transforming growth factor-beta type II receptor (TGFBR2) in the stromal compartment (n=77, P-value=0.0001), similar to the rate of glutathione S-transferase P1 (GSTP1) silencing. Xenografting of human prostate cancer epithelia, LNCaP, resulted in the epigenetic Tgfbr2 silencing of host mouse prostatic fibroblasts. Stromal Tgfbr2 promoter hypermethylation, initiated by LNCaP cells, was found to be dependent on interleukin 6 expression, based on neutralizing antibody studies. We further found that pharmacologic and transgenic knockout of TGF-β responsiveness in prostatic fibroblasts induced Gstp1 promoter methylation. It is known that TGF-β promotes DNA stability, however, the mechanism is not well understood. Both prostatic human CAF and mouse transgenic knockout of Tgbr2 had elevated DNA methyltransferase I (DNMT1) activity and histone H3 lysine 9 trimethylation (H3K9me3) to suggest greater promoter methylation. Interestingly, the conditional knockout of Tgfbr2 in mouse prostatic fibroblasts, in modeling epigenetic silencing of Tgfbr2, had greater epigenetic gene silencing of multiple DNA damage repair and oxidative stress response genes, based on promoter methylation array analysis. Homologous gene silencing was validated by reverse transcriptase (RT)-PCR in mouse and human prostatic CAF. Not surprisingly, DNA damage repair gene silencing in the prostatic stromal cells corresponded with the presence of DNA damage. Restoring the expression of the epigenetically silenced genes in wild-type fibroblasts with radiation-induced DNA damage reduced tumor progression. Tumor progression was inhibited even when epigenetic silencing was reversed in the Tgfbr2-knockout prostatic fibroblasts. Taken together, fibroblastic epigenetic changes causative of DNA damage, initiated by association with cancer epithelia, is a dominant mediator of tumor progression over TGF-β responsiveness. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.
- Author
-
Rodriguez-Paredes, M, Martinez de Paz, A, Simó-Riudalbas, L, Sayols, S, Moutinho, C, Moran, S, Villanueva, A, Vázquez-Cedeira, M, Lazo, P A, Carneiro, F, Moura, C S, Vieira, J, Teixeira, M R, and Esteller, M
- Subjects
LUNG cancer treatment ,GENE amplification ,HISTONE methyltransferases ,CARCINOGENESIS ,MESSENGER RNA ,CANCER cell culture ,LABORATORY mice ,TUMOR proteins - Abstract
Disruption of the histone modification patterns is one of the most common features of human tumors. However, few genetic alterations in the histone modifier genes have been described in tumorigenesis. Herein we show that the histone methyltransferase SETDB1 undergoes gene amplification in non-small and small lung cancer cell lines and primary tumors. The existence of additional copies of the SETDB1 gene in these transformed cells is associated with higher levels of the corresponding mRNA and protein. From a functional standpoint, the depletion of SETDB1 expression in amplified cells reduces cancer growth in cell culture and nude mice models, whereas its overexpression increases the tumor invasiveness. The increased gene dosage of SETDB1 is also associated with enhanced sensitivity to the growth inhibitory effect mediated by the SETDB1-interfering drug mithramycin. Overall, the findings identify SETDB1 as a bona fide oncogene undergoing gene amplification-associated activation in lung cancer and suggest its potential for new therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Context-specific regulation of cancer epigenomes by histone and transcription factor methylation.
- Author
-
Sarris, M, Nikolaou, K, and Talianidis, I
- Subjects
EPIGENOMICS ,CANCER genetics ,HISTONE methylation ,TRANSCRIPTION factors ,GENE expression ,HISTONE demethylases ,CHROMATIN - Abstract
Altered expression or activity of histone lysine methylases and demethylases in cancer lead to aberrant chromatin modification patterns, which contribute to uncontrolled cell proliferation via cancer-specific deregulation of gene expression programs or the induction of genome instability. Several transcription factors that regulate growth-associated genes undergo lysine methylation, expanding the repertoire of regulatory targets modulated by histone-methylating enzymes during tumorigenesis. In certain specific tumor types or specific physiological conditions, these enzymes may trigger chromatin structure and/or transcription factor activity changes that result in opposite effects on cancer initiation or progression. The mechanisms of such context-specific dual functions and those involved in the crosstalk between factor and histone modifications are subject to extensive research, which is beginning to shed light into this novel level of complexity of cancer-related epigenetic pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. miR-143 regulates hexokinase 2 expression in cancer cells.
- Author
-
Peschiaroli, A, Giacobbe, A, Formosa, A, Markert, E K, Bongiorno-Borbone, L, Levine, A J, Candi, E, D'Alessandro, A, Zolla, L, Finazzi Agrò, A, and Melino, G
- Subjects
GLUCOKINASE ,MICRORNA ,GENETIC regulation ,CANCER cells ,GENE expression ,GLUCOSE metabolism ,KERATINOCYTES ,GLYCOLYSIS - Abstract
Tumor cells activate pathways that facilitate and stimulate glycolysis even in the presence of adequate levels of oxygen in order to satisfy their continuous need of molecules, such as nucleotides, ATP and fatty acids, necessary to support their rapid proliferation. Accordingly, a variety of human tumors are characterized by elevated expression levels of the hexokinase 2 isoform (HK2). Although different molecular mechanisms, including genetic and epigenetic mechanisms, have been suggested to account for the altered expression of HK2 in tumors, the potential role of microRNAs (miRNAs) in the regulation of HK2 expression has not been evaluated. Here, we report that miR-143 inhibits HK2 expression via a conserved miR-143 recognition motif located in the 3′-untranslated region (3′UTR) of HK2 mRNA. We demonstrate that miR143 inhibits HK2 expression both in primary keratinocytes and in head and neck squamous cell carcinoma (HNSCC)-derived cell lines. Importantly, we found that miR-143 inversely correlates with HK2 expression in HNSCC-derived cell lines and in primary tumors. We also report that the miRNA-dependent regulation of hexokinase expression is not limited to HK2 as miR-138 targets HK1 via a specific recognition motif located in its 3′UTR. All these data unveil a new miRNA-dependent mechanism of regulation of hexokinase expression potentially important in the regulation of glucose metabolism of cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
- Author
-
Babbio, F, Pistore, C, Curti, L, Castiglioni, I, Kunderfranco, P, Brino, L, Oudet, P, Seiler, R, Thalman, G N, Roggero, E, Sarti, M, Pinton, S, Mello-Grand, M, Chiorino, G, Catapano, C V, Carbone, G M, and Bonapace, I M
- Subjects
PROSTATE cancer prognosis ,DNA methylation ,UBIQUITIN ,EPIGENETICS ,GENE silencing ,TUMOR suppressor genes ,CELL transformation ,PROSTATE cancer treatment - Abstract
Epigenetic silencing of tumour suppressor genes is an important mechanism involved in cell transformation and tumour progression. The Set and RING-finger-associated domain-containing protein UHRF1 might be an important link between different epigenetic pathways. Here, we report that UHRF1 is frequently overexpressed in human prostate tumours and has an important role in prostate cancer pathogenesis and progression. Analysis of human prostate cancer samples by microarrays and immunohistochemistry showed increased expression of UHRF1 in about half of the cases. Moreover, UHRF1 expression was associated with reduced overall survival after prostatectomy in patients with organ-confined prostate tumours (P<0.0001). UHRF1 expression was negatively correlated with several tumour suppressor genes and positively with the histone methyltransferase (HMT) EZH2 both in prostate tumours and cell lines. UHRF1 knockdown reduced proliferation, clonogenic capability and anchorage-independent growth of prostate cancer cells. Depletion of UHRF1 resulted in reactivation of several tumour suppressor genes. Gene reactivation upon UHRF1 depletion was associated with changes in histone H3K9 methylation, acetylation and DNA methylation, and impaired binding of the H3K9 HMT Suv39H1 to the promoter of silenced genes. Co-immunoprecipitation experiments showed direct interaction between UHRF1 and Suv39H1. Our data support the notion that UHRF1, along with Suv39H1 and DNA methyltransferases, contributes to epigenetic gene silencing in prostate tumours. This could represent a parallel and convergent pathway to the H3K27 methylation catalyzed by EZH2 to synergistically promote inactivation of tumour suppressor genes. Deregulated expression of UHRF1 is involved in the prostate cancer pathogenesis and might represent a useful marker to distinguish indolent cancer from those at high risk of lethal progression. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
13. Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.
- Author
-
Taniguchi, H, Jacinto, F V, Villanueva, A, Fernandez, A F, Yamamoto, H, Carmona, F J, Puertas, S, Marquez, V E, Shinomura, Y, Imai, K, and Esteller, M
- Subjects
BREAST cancer treatment ,GENE silencing ,METHYLTRANSFERASES ,CANCER treatment ,KRUPPEL-like factors ,TUMOR suppressor genes ,MORTALITY - Abstract
The Kruppel-like factor (KLF) proteins are multitasked transcriptional regulators with an expanding tumor suppressor function. KLF2 is one of the prominent members of the family because of its diminished expression in malignancies and its growth-inhibitory, pro-apoptotic and anti-angiogenic roles. In this study, we show that epigenetic silencing of KLF2 occurs in cancer cells through direct transcriptional repression mediated by the Polycomb group protein Enhancer of Zeste Homolog 2 (EZH2). Binding of EZH2 to the 5′-end of KLF2 is also associated with a gain of trimethylated lysine 27 histone H3 and a depletion of phosphorylated serine 2 of RNA polymerase. Upon depletion of EZH2 by RNA interference, short hairpin RNA or use of the small molecule 3-Deazaneplanocin A, the expression of KLF2 was restored. The transfection of KLF2 in cells with EZH2-associated silencing showed a significant anti-tumoral effect, both in culture and in xenografted nude mice. In this last setting, KLF2 transfection was also associated with decreased dissemination and lower mortality rate. In EZH2-depleted cells, which characteristically have lower tumorigenicity, the induction of KLF2 depletion 'rescued' partially the oncogenic phenotype, suggesting that KLF2 repression has an important role in EZH2 oncogenesis. Most importantly, the translation of the described results to human primary samples demonstrated that patients with prostate or breast tumors with low levels of KLF2 and high expression of EZH2 had a shorter overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer.
- Author
-
Jiang, J, Liu, W, Guo, X, Zhang, R, Zhi, Q, Ji, J, Zhang, J, Chen, X, Li, J, Gu, Q, Liu, B, Zhu, Z, and Yu, Y
- Subjects
NEOVASCULARIZATION ,STOMACH cancer ,METASTASIS ,GENE expression ,UMBILICAL veins ,VASCULAR endothelium ,CHICKEN embryos ,ANTINEOPLASTIC agents - Abstract
The overexpression of IRX1 gene correlates with the growth arrest in gastric cancer. Furthermore, overexpression of IRX1 gene suppresses peritoneal spreading and long distance metastasis. To explore the precise mechanisms, we investigated whether restoring IRX1 expression affects the angiogenesis or vasculogenic mimicry (VM). Human umbilical vein endothelial cells (HUVECs) and chick embryo and SGC-7901 gastric cancer cells were used for angiogenesis and VM analysis. Small interfering RNA was used for analyzing the function of BDKRB2, a downstream target gene of IRX1. As results, the remarkable suppression on peritoneal spreading and pulmonary metastasis of SGC-7901 cells by IRX1 transfectant correlates to reduced angiogenesis as well as VM formation. Using the supernatant from SGC-7901/IRX1 cells, we found a strong inhibiting effect on angiogenesis both in vitro and in chick embryo. SGC-7901/IRX1 cells revealed strong inhibiting effect on VM formation too. By gene-specific RNA interference for BDKRB2, or its effector PAK1, we got an effective inhibition on tube formation, cell proliferation, cell migration and invasion in vitro. In conclusion, enforcing IRX1 expression effectively suppresses peritoneal spreading and pulmonary metastasis via anti-angiogenesis and anti-VM mechanisms, in addition to previously found cell growth and invasion. BDKRB2 and its downstream effector might be potential targets for anti-cancer strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.
- Author
-
Banerjee, R, Mani, R-S, Russo, N, Scanlon, C S, Tsodikov, A, Jing, X, Cao, Q, Palanisamy, N, Metwally, T, Inglehart, R C, Tomlins, S, Bradford, C, Carey, T, Wolf, G, Kalyana-Sundaram, S, Chinnaiyan, A M, Varambally, S, and D'Silva, N J
- Subjects
TUMOR suppressor genes ,GENE silencing ,GENE expression ,SQUAMOUS cell carcinoma ,PANCREATIC cancer ,METHYLTRANSFERASES ,HISTONES ,HEAD & neck cancer - Abstract
Rap1GAP is a critical tumor suppressor gene that is downregulated in multiple aggressive cancers, such as head and neck squamous cell carcinoma, melanoma and pancreatic cancer. However, the mechanistic basis of rap1GAP downregulation in cancers is poorly understood. By employing an integrative approach, we demonstrate polycomb-mediated repression of rap1GAP that involves Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase in head and neck cancers. We further demonstrate that the loss of miR-101 expression correlates with EZH2 upregulation, and the concomitant downregulation of rap1GAP in head and neck cancers. EZH2 represses rap1GAP by facilitating the trimethylation of histone 3 at lysine 27, a mark of gene repression, and also hypermethylation of rap1GAP promoter. These results provide a conceptual framework involving a microRNA-oncogene-tumor suppressor axis to understand head and neck cancer progression. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
16. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.
- Author
-
Li, X, Martinez-Ferrer, M, Botta, V, Uwamariya, C, Banerjee, J, and Bhowmick, N A
- Subjects
PROSTATE cancer ,CARCINOGENESIS ,CANCER cells ,CELL communication ,CASTRATION ,HYDROGEN peroxide ,TRANSFORMING growth factors-beta ,MYC oncogenes - Abstract
Stromal-epithelial interactions dictate prostate tumorigenesis and response to castration. Hydrogen peroxide-inducible clone 5 (Hic-5/ARA55) is a transforming growth factor-beta (TGF-β)-induced coactivator of androgen receptor (AR) expressed in the prostate stroma. Interestingly, following castration, we identified epithelial expression of Hic-5/ARA55 in mouse and human prostate tissues. To determine the role of epithelial Hic-5 in prostate cancer progression and castration responsiveness, we compared LNCaP cells having Hic-5 stably expressed with the parental LNCaP cells following tissue recombination xenografts with mouse prostate stromal cells. We previously identified knocking out prostate stromal TGF-β signaling potentiated castrate-resistant prostate tumors, in a Wnt-dependent manner. The LNCaP chimeric tumors containing prostate fibroblasts conditionally knocked out for the TGF-β type II receptor (Tgfbr2-KO) resulted in larger, more invasive, and castration-resistant tumors compared those with floxed (control) stromal cells. However, the LNCaP-Hic5 associated with Tgfbr2-KO fibroblasts generated chimeric tumors with reduced tumor volume, lack of invasion and restored castration dependence. Neutralization of canonical Wnt signaling is shown to reduce prostate tumor size and restore regression following castration. Thus, we hypothesized that epithelial Hic-5/ARA55 expression negatively regulated Wnt signaling. The mechanism of the Hic-5/ARA55 effects on castration was determined by analysis of the c-myc promoter. C-myc luciferase reporter activity suggested Hic-5/ARA55 expression inhibited c-myc activity by β-catenin. Sequential ChIP analysis indicated β-catenin and T-cell-specific 4 (TCF4) bound the endogenous c-myc promoter in the absence of Hic-5 expression. However, the formation of a TCF4/Hic-5 repressor complex inhibited c-myc promoter activity, by excluding β-catenin binding with TCF4 on the promoter. The data indicate Hic-5/ARA55 expression in response to castration-enabled epithelial regression through the repression of c-myc gene at the chromatin level. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells.
- Author
-
Pommier, A. J. C., Alves, G., Viennois, E., Bernard, S., Communal, Y., Sion, B., Marceau, G., Damon, C., Mouzat, K., Caira, F., Baron, S., and Lobaccaro, J. M. A.
- Subjects
PROSTATE cancer treatment ,CELL receptors ,CELL membranes ,LIVER cells ,LIPID synthesis ,APOPTOSIS ,HOMEOSTASIS ,ATOMIC force microscopy ,PHYSIOLOGY - Abstract
Cholesterol is a structural component of lipid rafts within the plasma membrane. These domains, used as platforms for various signaling molecules, regulate cellular processes including cell survival. Cholesterol contents are tightly correlated with the structure and function of lipid rafts. Liver X receptors (LXRs) have a central role in the regulation of cholesterol homeostasis within the cell. Therefore, we investigated whether these nuclear receptors could modulate lipid raft signaling and consequently alter prostate cancer (PCa) cell survival. Treatment with the synthetic LXR agonist T0901317 downregulated the AKT survival pathway and thus induced apoptosis of LNCaP PCa cells in both xenografted nude mice and cell culture. The decrease in tumor cholesterol content resulted from the upregulation of ABCG1 and the subsequent increase in reverse cholesterol transport. RNA interference experiments showed that these effects were mediated by LXRs. Atomic force microscopy scanning of the inner plasma membrane sheet showed smaller and thinner lipid rafts after LXR stimulation, associated with the downregulation of AKT phosphorylation in these lipid rafts. Replenishment of cell membranes with exogenous cholesterol antagonized these effects, showing that cholesterol is a key modulator in this process. Altogether, pharmacological modulation of LXR activity could thus reduce prostate tumor growth by enhancing apoptosis in a lipid raft-dependent manner. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.
- Author
-
Palamakumbura, A. H., Vora, S. R., Nugent, M. A., Kirsch, K. H., Sonenshein, G. E., and Trackman, P. C.
- Subjects
LYSYL oxidase ,PROSTATE cancer ,TUMOR suppressor proteins ,CELL proliferation ,RAS proteins ,FIBROBLAST growth factors - Abstract
Enhanced RAS signaling and decreased androgen dependence of prostate cancer cells accompany poor clinical outcomes. Elevated autocrine fibroblast growth factors 2 (FGF-2) signaling promotes prostate cancer cell growth and survival. Expression of lysyl oxidase (LOX) inhibits RAS transforming activity. LOX is secreted as 50 kDa pro-LOX protein and then undergoes extracellular proteolytic processing to form ∼30 kDa LOX enzyme and ∼18 kDa propeptide (LOX-PP). We have previously shown that LOX-PP inhibits breast cancer cell transformation and tumor formation, but mechanisms of action of LOX-PP have not been fully elucidated. Here we report that LOX expression is reduced in prostate cancer cell lines and that recombinant LOX-PP protein inhibits serum-stimulated DNA synthesis and MEK/ERK and PI3K/AKT pathways in DU 145 and PC-3 androgen-independent cell lines. In DU 145 cells, treatment with a pharmacologic FGF-receptor inhibitor or a neutralizing anti-FGFR1 antibody mimicked LOX-PP inhibition of serum-stimulated DNA synthesis. FGF-2-stimulated DNA synthesis, ERK1/2, AKT and FRS2α activation were found all to be inhibited by LOX-PP in DU 145 cells. LOX-PP reduced specific binding of FGF-2 to DU 145 cells, suggesting that LOX-PP targets FGF signaling at the receptor. Interestingly, PC-3 cells did not respond to FGF-2, consistent with previous reports. We conclude that LOX-PP inhibits proliferation of DU 145 cells by interfering with FGFR(s) binding and signaling, and that LOX-PP has other mechanisms of action in PC-3 cells. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
19. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
- Author
-
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R-S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., Kleer, C. G., Varambally, S., and Chinnaiyan, A. M.
- Subjects
CYTOLOGICAL research ,CADHERINS ,STEM cells ,CELL proliferation ,EPITHELIAL cells - Abstract
Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.Oncogene (2008) 27, 7274–7284; doi:10.1038/onc.2008.333; published online 22 September 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
20. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
- Author
-
Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C. M., Deshaies, R. J., and Sakamoto, K. M.
- Subjects
PROTEOLYSIS ,EUKARYOTIC cells ,PEPTIDES ,CANCER cells ,RETINOBLASTOMA ,PHOSPHORYLATION ,UBIQUITIN ,GENITAL cancer ,CANCER treatment - Abstract
Proteolysis targeting chimeric molecules (Protacs) target proteins for destruction by exploiting the ubiquitin-dependent proteolytic system of eukaryotic cells. We designed two Protacs that contain the peptide ‘degron’ from hypoxia-inducible factor-1α, which binds to the Von –Hippel–Lindau (VHL) E3 ubiquitin ligase complex, linked to either dihydroxytestosterone that targets the androgen receptor (AR; Protac-A), or linked to estradiol (E2) that targets the estrogen receptor-α (ERα; Protac-B). We hypothesized that these Protacs would recruit hormone receptors to the VHL E3 ligase complex, resulting in the degradation of receptors, and decreased proliferation of hormone-dependent cell lines. Treatment of estrogen-dependent breast cancer cells with Protac-B induced the degradation of ERα in a proteasome-dependent manner. Protac-B inhibited the proliferation of ERα-dependent breast cancer cells by inducing G
1 arrest, inhibition of retinoblastoma phosphorylation and decreasing expression of cyclin D1, progesterone receptors A and B. Protac-B treatment did not affect the proliferation of estrogen-independent breast cancer cells that lacked ERα expression. Similarly, Protac-A treatment of androgen-dependent prostate cancer cells induced G1 arrest but did not affect cells that do not express AR. Our results suggest that Protacs specifically inhibit the proliferation of hormone-dependent breast and prostate cancer cells through degradation of the ERα and AR, respectively.Oncogene (2008) 27, 7201–7211; doi:10.1038/onc.2008.320; published online 15 September 2008 [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
21. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
- Author
-
Asim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., and Mukhtar, H.
- Subjects
CANCER ,PROSTATE cancer ,CANCER cells ,PROSTATE-specific antigen ,TUMOR antigens ,ANDROGENS - Abstract
Prostate cancer is one of the most prominent malignancies of elderly men in many Western countries including Europe and the United States with increasing trend worldwide. The growth of normal prostate as well as of prostate carcinoma cells depends on functional androgen receptor (AR) signaling. AR manifests the biological actions of androgens and its transcriptional activity is known to be influenced by signal transduction pathways. Here we show that Src, a nonreceptor tyrosine kinase, is overexpressed in androgen-independent prostate carcinoma C4-2 cells. Interestingly, the expression of Src was found to progressively increase (up to threefold) in transgenic adenocarcinoma of mouse prostate mice as a function of age and cancer progression. Blocking Src kinase function by a specific inhibitor, PP2, resulted in decreased AR transactivation function on two different reporters, mouse mammary tumor virus (MMTV) and prostate-specific antigen (PSA). Consistent with this, overexpression of a functional Src mutant also led to a dramatic decrease in AR transactivation potential in a hormone-dependent manner. Interference with Src function in C4-2 cells led to decreased recruitment of AR on the target gene PSA enhancer and also resulted in the abrogation of hormone-dependent PSA transcript induction. Src inhibition also led to a dramatic decrease in the cell invasion in addition to decreasing the cellular growth. We suggest that targeting Src kinase could be an effective strategy to inhibit prostate cancer growth and metastasis.Oncogene (2008) 27, 3596–3604; doi:10.1038/sj.onc.1211016; published online 28 January 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
22. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.
- Author
-
Nuytten, M., Beke, L., Van Eynde, A., Ceulemans, H., Beullens, M., Van Hummelen, P., Fuks, F., and Bollen, M.
- Subjects
PHOSPHOPROTEIN phosphatases ,IMMUNOSPECIFICITY ,IMMUNOGLOBULIN idiotypes ,GENETIC regulation ,GENE silencing ,BIOSYNTHESIS - Abstract
EZH2 is a Polycomb group (PcG) protein that promotes the late-stage development of cancer by silencing a specific set of genes, at least in part through trimethylation of associated histone H3 on Lys 27 (H3K27). Nuclear inhibitor of protein phosphatase-1 (NIPP1) is a ubiquitously expressed transcriptional repressor that has binding sites for the EZH2 interactor EED. Here, we examine the contribution of NIPP1 to EZH2-mediated gene silencing. Studies on NIPP1-deficient cells disclose a widespread and essential role of NIPP1 in the trimethylation of H3K27 by EZH2, not only in the onset of this trimethylation during embryonic development, but also in the maintenance of this repressive mark in proliferating cells. Consistent with this notion, EZH2 and NIPP1 silence a common set of genes, as revealed by gene-expression profiling, and NIPP1 is associated with established Polycomb target genes and with genomic regions that are enriched in Polycomb targets. Furthermore, most NIPP1 target genes are trimethylated on H3K27 and the knockdown of either NIPP1 or EZH2 is often associated with a loss of this modification. Our data reveal that NIPP1 is required for the global trimethylation of H3K27 and is implicated in gene silencing by EZH2.Oncogene (2008) 27, 1449–1460; doi:10.1038/sj.onc.1210774; published online 3 September 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
23. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth.
- Author
-
Migliaccio, A., Varricchio, L., De Falco, A., Castoria, G., Arra, C., Yamaguchi, H., Ciociola, A., Lombardi, M., Di Stasio, R., Barbieri, A., Baldi, A., Barone, M. V., Appella, E., and Auricchio, F.
- Subjects
BREAST cancer ,PROSTATE cancer ,STEROID hormones ,EPIDERMAL growth factor ,ESTRADIOL ,CELL cycle ,ONCOGENES - Abstract
In human mammary and prostate cancer cells, steroid hormones or epidermal growth factor (EGF) trigger association of the androgen receptor (AR)-estradiol receptor (ER) (α or β) complex with Src. This interaction activates Src and affects the G1 to S cell cycle progression. In this report, we identify the sequence responsible for the AR/Src interaction and describe a 10 amino-acid peptide that inhibits this interaction. Treatment of the human prostate or mammary cancer cells (LNCaP or MCF-7, respectively) with nanomolar concentrations of this peptide inhibits the androgen- or estradiol-induced association between the AR or the ER and Src the Src/Erk pathway activation, cyclin D1 expression and DNA synthesis, without interfering in the receptor-dependent transcriptional activity. Similarly, the peptide prevents the S phase entry of LNCaP and MCF-7 cells treated with EGF as well as mouse embryo fibroblasts stimulated with androgen or EGF. Interestingly, the peptide does not inhibit the S phase entry and cytoskeletal changes induced by EGF or serum treatment of AR-negative prostate cancer cell lines. The peptide is the first example of a specific inhibitor of steroid receptor-dependent signal transducing activity. The importance of these results is highlighted by the finding that the peptide strongly inhibits the growth of LNCaP xenografts established in nude mice.Oncogene (2007) 26, 6619–6629; doi:10.1038/sj.onc.1210487; published online 7 May 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
24. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression.
- Author
-
Cronauer, M. V., Ince, Y., Engers, R., Rinnab, L., Weidemann, W., Suschek, C. V., Burchardt, M., Kleinert, H., Wiedenmann, J., Sies, H., Ackermann, R., and Kröncke, K.-D.
- Subjects
ANDROGENS ,PROSTATE cancer ,NITRIC oxide ,DNA-binding proteins ,INFLAMMATION ,NITRIC-oxide synthases ,CARCINOGENESIS - Abstract
Chronic inflammation increases the risk of cancer and many cancers, including prostate cancer, arise at sites of chronic inflammation. Inducible nitric oxide synthase (iNOS) is an enzyme dominantly expressed during inflammatory reactions. Although synthesis of high amounts of nitric oxide (NO) by iNOS has been demonstrated in pathophysiological processes, such as acute or chronic inflammation, autoimmune diseases or tumorigenesis, the role of iNOS activity in most of these diseases is poorly understood. Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active. In vitro, NO inhibits androgen receptor-dependent promoter activity and prostate specific antigen production as well as DNA-binding activity of the androgen receptor (AR) in a concentration-dependent manner. Inhibition of the activity of androgen receptor-dependent reporter constructs is neither owing to diminished AR protein levels nor owing to an inhibition of its nuclear import. In addition, NO inhibits the proliferation of androgen receptor-positive prostate cancer cells significantly more efficiently than proliferation of androgen receptor-negative prostate cancer cells. In summary, our findings suggest that intratumoral iNOS activity favors development of prostate cancer cells that are able to proliferate androgen receptor-independently, thereby promoting prostate tumor progression.Oncogene (2007) 26, 1875–1884. doi:10.1038/sj.onc.1209984; published online 18 September 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
25. Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells.
- Author
-
Corral, R. S., Iñiguez, M. A., Duque, J, López-Pérez, R., and Fresno, M.
- Subjects
BOMBESIN ,T cells ,CELL migration ,CANCER cell growth ,COLON cancer ,CYCLOSPORINE - Abstract
Cyclooxygenase-2 (Cox-2), the gastrin-release peptide (GRP) and its cognate receptor (GRP-R) are overexpressed in a significant percentage of colorectal carcinomas and are associated with cell growth, invasiveness and tumor progression. However, a molecular link between all of them in adenocarcinomas has not been established. Here, we show that bombesin (BBS), a GRP homolog, stimulates the expression of Cox-2 mRNA and protein in human colon adenocarcinoma Caco-2 cells, resulting in enhanced release of prostaglandin E
2 . These effects were markedly inhibited by the specific BBS antagonist RC-3940-II. BBS promotes the activation of the nuclear factor of activated T cells (NFAT) through a Ca2+ /calcineurin (Cn)-linked pathway. Upon BBS stimulation, the NFATc1 isoform translocates into the nucleus with a concomitant increase in NFATc1 binding to two specific recognition sites in the promoter region of the Cox-2 gene. Furthermore, inhibition of Cn activity by the immunosuppressive drug cyclosporin A impaired NFAT activation and diminished Cox-2 expression in BBS-stimulated cells. Interestingly, BBS pretreatment strongly enhances the invasive capacity of carcinoma cells, effect which was inhibited by a Cox-2-specific inhibitor. These findings provide the first evidence for the involvement of the Ca2+ /Cn/NFAT pathway in BBS-mediated induction of genes involved in colon carcinoma invasiveness such as Cox-2.Oncogene (2007) 26, 958–969. doi:10.1038/sj.onc.1209856; published online 14 August 2006 [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
26. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas.
- Author
-
Alchanati, I., Nallar, S. C., Sun, P., Gao, L., Hu, J., Stein, A., Yakirevich, E., Konforty, D., Alroy, I., Zhao, X., Reddy, S. P., Resnick, M. B., and Kalvakolanu, D. V.
- Subjects
CELL growth ,CANCER ,CYTOKINES ,CELL death ,TRANSCRIPTION factors ,TUMOR suppressor proteins ,TUMORS - Abstract
Gene associated with retinoid interferon-induced mortality (GRIM)-19, an inhibitor of transcription factor STAT3, was originally identified as a critical regulatory protein in a genetic screen that was designed to identify the gene products necessary for Interferon (IFN)-β- and retinoic acid-induced cell death. Over expression of GRIM-19 activates cell death. Conversely, inactivation of its expression promotes cell growth. STAT3 is a transcription factor that regulates gene expression in response to multiple extra cellular growth factors. In contrast to its normal feedback inhibition, a constitutive activation of STAT3 has been documented in several tumors. Although many STAT3-inhibitors are described, their relevance to human cancer is unclear. In an attempt to define the molecular alterations associated with human renal cell carcinoma (RCC) using mass spectrometry, we have discovered that expression of GRIM-19 is lost or severely depressed in a number of primary RCC and in some urinogenital tumors. Using an RCC cell line, we show that down regulation of GRIM-19 promotes tumor growth via an augmentation of STAT3-dependent gene expression. These studies for the first time show a tumor-suppressor like activity of GRIM-19.Oncogene (2006) 25, 7138–7147. doi:10.1038/sj.onc.1209708; published online 29 May 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
27. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis.
- Author
-
Bandyopadhyay, Sucharita, Pai, Sudha K., Watabe, Misako, Gross, Steven C., Hirota, Shigeru, Hosobe, Sadahiro, Tsukada, Taisei, Miura, Kunio, Saito, Ken, Markwell, Stephen J., Ying Wang, Huggenvik, Jodi, Pauza, Mary E., Iiizumi, Megumi, and Watabe, Kounosuke
- Subjects
FATTY acid synthesis ,FATTY acids ,CARBOXYLIC acids ,ANTINEOPLASTIC agents ,TUMOR suppressor genes - Abstract
Fatty acid synthase (FAS), a key enzyme of the fatty acid biosynthetic pathway, has been shown to be overexpressed in various types of human cancer and is, therefore, considered to be an attractive target for anticancer therapy. However, the exact mechanism of overexpression of the FAS gene in tumor cells is not well understood. In this report, we demonstrate that the expression of the tumor suppressor gene PTEN has a significant inverse correlation with FAS expression in the case of prostate cancer in the clinical setting, and inhibition of the PTEN gene leads to the overexpression of FAS in vitro. We also found that the combination of the expression status of these two genes is a better prognostic marker than either gene alone. Furthermore, our results indicate that the specific inhibition of FAS gene by siRNA leads to apoptosis of prostate tumor cells, and inhibition of PI 3-kinase pathway synergizes with FAS siRNA to enhance tumor cell death. These results provide a strong rationale for exploring the therapeutic use of an inhibitor of the PTEN signaling pathway in conjunction with the FAS siRNA to inhibit prostate tumor growth.Oncogene (2005) 24, 5389–5395. doi:10.1038/sj.onc.1208555; published online 16 May 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
28. IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10R a chain in human primary prostate cancer cell lines.
- Author
-
Stearns, Mark E, Hu, Youji, and Wang, Min
- Subjects
INTERLEUKIN-10 ,TYROSINE ,PHOSPHORYLATION ,PROSTATE cancer ,GREEN fluorescent protein - Abstract
Interleukin 10 (IL-10) stimulates rapid nuclear translocation and binding of a 22?kDa protein, termed interleukin 10 enhancer 1 (IL-10E1), to a novel enhancer element (i.e. HTE-1) of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene to upregulate TIMP-1 expression. IL-10E1 signaling involves tyrosine phosphorylation of the IL-10R JAK1 (Janus kinase) and TYK2 (tyrosine kinase) receptor kinases and tyrosine phosphorylation of two tyrosine moieties (Y57 and Y62) of a LIM domain of the IL-10E1 protein. In this paper, the studies showed that two tyrosine residues (Tyr
446 and Tyr496 ) located in the cytoplasmic domain of the IL-10R a chain were required for receptor function, and for phosphorylation and activation of IL-10E1. Immunoprecipitation studies revealed that 12 amino-acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated IL-10E1 and blocked ligand-dependent IL-10E1 phosphorylation in a cell-free system. In contrast, peptides containing serine substitutions for Tyr446 and Tyr496 , and tyrosine-phosphorylated peptides containing Tyr230 or Tyr252/259 did not prevent IL-10E1 activation or signaling. To confirm these observations in vivo, fusion protein constructs were made between a modified form of green fluorescent protein or GFP and the intact IL-10E1 protein (IL-10E1-MmGFP) and n-terminal peptides of the IL-10E1 protein (i.e. nt-nls-MmGFP and mutant sequences identified as nt-nls mC61-MmGFP and nt-nls mY57/mY62-MmGFP peptides). Confocal microscopy revealed that IL-10 triggered transport to the nucleus of IL-10E1-MmGFP, nt-nls-MmGFP, and nt-nls mC61-MmGFP by 10-30?min in HPCA-10a (human prostrate cancer cells; derived from Gleason sum 10 tumor tissue) cells. IL-10 failed to induce nuclear translocation of the mY57/mY62-MmGFP peptides with point mutations of the two tyrosine groups. Coinjection of nt-nls-MmGFP with the IL-10R... [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
29. Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor.
- Author
-
Chesire, Dennis R and Isaacs, William B
- Subjects
PROSTATE cancer ,INTERLEUKIN-2 ,GENE expression ,TRANSCRIPTION factors - Abstract
β-catenin signaling may contribute to prostate cancer (CaP) progression. Although β-catenin is known to upregulate T cell factor (TCF) target gene expression in CaP cells, recent evidence demonstrates its capacity to enhance ligand-dependent androgen receptor (AR) function. Thus, we wished to further understand the interaction between these two pathways. We find in both CaP cells (CWR22-Rv1, LAPC-4, DU145) and non-CaP cells (HEK-293, TSU, SW480, HCT-116) that β-catenin/TCF-related transcription (CRT), as measured by activation of a synthetic promoter and that of cyclin D1, is inhibited by androgen treatment. This inhibition is AR-dependent, as it only occurs in cells expressing AR endogenously or transiently, and is abrogated by AR antagonists. Additional analyses convey that the ligand-dependent nature of CRT suppression depends on transactivation-competent AR in the nucleus, but not on indirect effects stemming from AR target gene expression. Given the recent work identifying an AR/β-catenin interaction, and from our finding that liganded AR does not prompt gross changes in the constitutive nuclear localization of TCF4 or mutant β-catenin, we hypothesized that transcription factor (i.e. AR and TCF) competition for β-catenin recruitment may explain, in part, androgen-induced suppression of CRT. To address this idea, we expressed an AR mutant lacking its DNA-binding domain (DBD). This receptor could not orchestrate ligand-dependent CRT repression, thereby providing support for those recent data implicating the AR DBD/LBD as necessary for β-catenin interaction. Further supporting this hypothesis, TCF/LEF over-expression counteracts androgen-induced suppression of CRT, and requires β-catenin binding activity to do so. Interestingly, TCF4 over-expression potently antagonizes AR function; however, this inhibition may occur independently of β-catenin/TCF4 interaction. These results from TCF4 over-expression analyses,... [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
30. C-Jun N-terminal kinase is required for phorbol ester- and thapsiarin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
- Author
-
Engedal, Nikolai, Korkmaz, Ceren G., and Saatcioglu, Fahri
- Subjects
PROTEIN kinases ,APOPTOSIS ,PROSTATE cancer ,CELL lines - Abstract
Presents information on a study which determined the importance of c-Jun N-terminal kinase for apoptosis in the androgen responsive prostate cancer cell line LNCaP. Results; Discussion; Methodology.
- Published
- 2002
- Full Text
- View/download PDF
31. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.
- Author
-
Deroanne, Christophe F., Bonjean, Karine, Servotte, Sandrine, Devy, Laetitia, Colige, Alain, Clausse, Nathalie, Blacher, Sylvia, Verdin, Eric, Foidart, Jean-Michel, Nusgens, Betty V., and Castronovo, Vincent
- Subjects
HISTONE deacetylase ,NEOVASCULARIZATION - Abstract
Investigates the effect of histone deacetylases (HDAC) inhibitors on different models of angiogenesis. Information on angiogenesis; Function of HDAC; Types of HDAC inhibitors; Factors that contribute to the blocking of HDAC activity.
- Published
- 2002
- Full Text
- View/download PDF
32. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model.
- Author
-
Reddy, Kaladhar B, McGowen, Richard, Schuger, Lucia, Visscher, Daniel, and Sheng, Shijie
- Subjects
TRANSGENIC mice ,HYPERPLASIA ,IMMUNOHISTOCHEMISTRY ,IN situ hybridization - Abstract
Maspin is a novel serine protease inhibitor (serpin) with tumor suppressive activity. To date, despite the mounting evidence implicating the potential diagnostic/prognostic and therapeutic value of maspin in breast and prostate carcinoma, the lack of a suitable animal model hampers the in vivo investigation on the role of maspin at different stages of tumor progression. In this study, we used MMTV/TGF-α transgenic mouse model to study the expression profile of maspin in mammary tumor progression. Histopathological examinations of MMTV/TGF-α transgenic mice revealed TGF-α expression leading to hyperproliferation, hyperplasia, and occasional carcinoma in mammary gland. Interestingly, when MMTV/TGF-α transgenic mice were breed to homozygocity, they also developed characteristic skin papillomas. Immunohistochemistry analysis of maspin expression in the breast tissues of TGF-α transgenic mice showed a direct correlation between down-regulation of maspin expression and tumor progression. The loss of maspin expression was concomitant with the critical transition from carcinoma in situ to invasive carcinoma. Subsequent in-situ hybridization analyses suggest that the down-regulation of maspin expression is primarily a transcriptional event. This data is consistent with the tumor suppressive role of maspin. Furthermore, our data suggests that MMTV/TGF-α transgenic mouse model is advantageous for in vivo evaluation of both the expression and the biological function of maspin during the slow multi-stage carcinogenesis of mammary gland. Oncogene (2001) 20, 6538–6543. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
33. The contradictions of the insulin-like growth factor 1 receptor.
- Author
-
Baserga, Renato
- Subjects
SOMATOMEDIN ,CELL differentiation ,CYTOSKELETON ,APOPTOSIS - Abstract
In recent years, the type 1 insulin-like growth factor receptor (IGF-IR) has emerged as a receptor that plays a very important role in the growth of cells, both in vivo and in vitro. The ability of the IGF-IR to induce mitogenesis and to promote survival of cells against a variety of apoptotic agents is well documented. Somewhat less known are other functions of the IGF-IR, like its ability to induce differentiation, to regulate cell size and to affect the organization of the cytoskeleton of cells. This review will focus on these lesser known functions of the IGF-IR. At the same time, we will emphasize how the IGF-IR can send contradictory signals, which depend on different domains of the receptor and the availability of downstream transducing molecules. Oncogene (2000) 19, 5574–5581. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
34. Comparative microarray analysis of gene expression during apoptosis-induction by growth factor deprivation or protein kinase C inhibition.
- Author
-
Brachat, Arndt, Pierrat, Benoit, Brüngger, Adrian, and Heim, Jutta
- Subjects
CELL death ,GENE expression ,MESSENGER RNA ,APOPTOSIS ,CELL cycle - Abstract
The transcriptional response of mouse pro-B cells to two different apoptotic stimuli was investigated. First, interleukin-3 (IL-3) deprivation was used to trigger programmed cell death in IL-3 dependent FL5.12 cells. Alternatively, cells were treated with the protein kinase C (PKC) inhibitor staurosporine. The temporal pattern of gene expression was followed with cDNA microarrays, covering over 8700 different mouse cDNA sequences corresponding to approximately 7900 unique genes. Messenger RNA levels of 315 genes were found to be regulated by more than twofold upon IL-3 removal, while 125 genes reacted to staurosporine treatment. Cross-comparison revealed an intersection of 34 genes similarly regulated in both pathways and thus representing candidates for common apoptosis regulators. For many expressed sequence tags (ESTs) our data suggest for the first time functions in the control of apoptosis, stress response or the cell cycle. IL-3 removal led to the repression of genes required for proliferation and to the induction of genes, linked to apoptotic and signaling pathways. Staurosporine caused predominantly activation of genes, some of which had previously been described to be involved in inflammation. Our findings indicate that cellular responses to both apoptotic stimuli influence various physiological pathways which had not previously been known to be linked. Oncogene (2000) 19, 5073–5082 [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
35. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway.
- Author
-
Saavedra, Harold I, Knauf, Jeffrey A, Shirokawa, Jill M, Wang, Jianwei, Ouyang, Bin, Elisei, Rosella, Stambrook, Peter J, and Fagin, James A
- Subjects
GENETIC mutation ,TUMORS ,GENOMES ,ONCOGENES ,CENTROSOMES - Abstract
Activating mutations of RAS are thought to be early events in the evolution of thyroid follicular neoplasms. We used a doxycycline-inducible expression system to explore the acute effects of H-RAS
V12 on genomic stability in thyroid PCCL3 cells. At 2–3 days (first or second cell cycle) there was a significant increase in the frequency of micronucleation. Treatment of cells with YVAD-CHO inhibited RAS-induced apoptosis, but had no effect on micronucleation. The effects of H-RASV12 were mediated by activation of MAPK, as treatment with PD98059 at concentrations verified to selectively inhibit MEK1 reduced the frequency of prevalence of cells with micronuclei. In addition, doxycycline-inducible expression of a constitutively active MEK1, but not of a mutant RAC1, mimicked the effects of H-RASV12 . The effects of H-RASV12 on genome destabilization were apparent even though the sequence of p53 in PCCL3 cells was confirmed to be wild-type. Acute activation of H-RASV12 evoked a proportional increase in both CREST negative and CREST positive micronuclei, indicating that both clastogenic and aneugenic effects were involved. H-RASV12 and activated MEK1 also induced centrosome amplification, and chromosome misalignment. Evidence that acute expression of constitutively activated RAS destabilizes the genome of PCCL3 cells is consistent with a mode of tumor initiation in which this oncogene promotes phenotypic progression by predisposing to large scale genomic abnormalities. Oncogene (2000) 19, 3948–3954 [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
36. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
- Author
-
Ghosh, Paramita M, Ghosh-Choudhury, Nandini, Moyer, Marissa L, Mott, Glen E, Thomas, Charles A, Foster, Barbara A, Greenberg, Norman M, and Kreisberg, Jeffrey I
- Subjects
CANCER cells ,PROSTATE cancer ,CELL lines - Abstract
Prostate cancer cells derived from transgenic mice with adenocarcinoma of the prostate (TRAMP cells) were treated with the HMG-CoA reductase inhibitor, lovastatin. This caused inactivation of the small GTPase RhoA, actin stress fiber disassembly, cell rounding, growth arrest in the G1 phase of the cell cycle, cell detachment and apoptosis. Addition of geranylgeraniol (GGOL) in the presence of lovastatin, to stimulate protein geranylgeranylation, prevented lovastatin's effects. That is, RhoA was activated, actin stress fibers were assembled, the cells assumed a flat morphology and cell growth resumed. The following observations support an essential role for RhoA in TRAMP cell growth: (1) TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein displayed few actin stress fibers and grew at a slower rate than controls (35 h doubling time for cells expressing RhoA (T19N) vs 20 h for untransfected cells); (2) TRAMP cells expressing constitutively active RhoA (Q63L) mutant protein displayed a contractile phenotype and grew faster than controls (13 h doubling time). Interestingly, addition of farnesol (FOL) with lovastatin, to stimulate protein farnesylation, prevented lovastatin-induced cell rounding, cell detachment and apoptosis, and stimulated cell spreading to a spindle shaped morphology. However, RhoA remained inactive and growth arrest persisted. The morphological effects of FOL addition were prevented in TRAMP cells expressing dominant-negative H-Ras (T17N) mutant protein. Thus, it appears that H-Ras is capable of inducing cell spreading, but incapable of supporting cell proliferation, in the absence of geranylgeranylated proteins like RhoA. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
37. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4.
- Author
-
Qiu, Guofang, Ahmed, Mansoor, Sells, Stephen F, Mohiuddin, Mohammed, Weinstein, Michael H, and Rangnekar, Vivek M
- Subjects
PROSTATE cancer ,TUMORS ,APOPTOSIS ,ANDROGENS ,XENOGRAFTS ,CANCER cells - Abstract
Par-4 is a widely expressed protein that sensitizes both prostatic and non-prostatic cells to apoptosis. Constitutive- or regulated- overexpression of Par-4 caused a reduction in the levels of the anti-apoptotic protein Bcl-2. Replenishment of Bcl-2 levels abrogated susceptibility to Par-4-dependent apoptosis, suggesting that Par-4-mediated apoptosis requires downmodulation of Bcl-2 levels. The inverse correlation between Par-4 and Bcl-2 expression was recapitulated in human prostate tumors. Par-4 but not Bcl-2 was detected in the secretory epithelium of benign prostatic tumors and in primary and metastatic prostate cancers that are apt to undergo apoptosis. Moreover, xenografts of human, androgen-dependent CWR22 tumors showed Par-4 but not Bcl-2 expression. By contrast, androgen-independent CWR22R tumors derived from the CWR22 xenografts showed mutually exclusive expression patterns of Par-4 and Bcl-2. These findings suggest a mechanism by which Par-4 may sensitize prostate tumor cells to apoptosis. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
38. ETS2 function is required to maintain the transformed state of human prostate cancer cells.
- Author
-
Sementchenko, Victor I, Schweinfest, Clifford W, Papas, Takis S, and Watson, Dennis K
- Subjects
TRANSCRIPTION factors ,PROSTATE cancer ,ONCOGENES ,CARCINOMA - Abstract
The contribution of the ETS2 transcription factor to the transformed state in prostate cancer cells has been assessed. Northern blot analysis easily detects ETS2 in DU145 and PC3, high grade human prostate cell lines, but ETS2 is not present in lower grade LNCaP cells. Stable transfection of PC3 and DU145 prostate cell lines with an antisense ETS2 vector or with a dominant negative ETS2 mutant significantly reduced the ability of DU145 and PC3 cells to form large colonies in soft agar. Thus, the presence of ETS2 is positively correlated with a more transformed phenotype and blockage of ETS2 function can reduce transformed properties of prostate cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
39. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate
- Author
-
He, Yongfeng, Johnson, Daniel T., Yang, Julie S., Wu, Huiqing, You, Sungyong, Yoon, Junhee, Lee, Dong-Hoon, Kim, Won Kyung, Aldahl, Joseph, Le, Vien, Hooker, Erika, Yu, Eun-Jeong, Geradts, Joseph, Cardiff, Robert D., and Sun, Zijie
- Published
- 2019
- Full Text
- View/download PDF
40. Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes
- Author
-
Zhou, Pei-Jie, Wang, Xiao, An, Na, Wei, Lianzi, Zhang, Long, Huang, Xingxu, Zhu, Helen He, Fang, Yu-Xiang, and Gao, Wei-Qiang
- Published
- 2019
- Full Text
- View/download PDF
41. Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis
- Author
-
Birnbaum, Michael D., Zhao, Ning, Moorthy, Balaji T., Patel, Devang M., Kryvenko, Oleksandr N., Heidman, Laine, Kumar, Akhilesh, Morgan, William M., Ban, Yuguang, Reis, Isildinha M., Chen, Xi, Gonzalgo, Mark L., Jorda, Merce, Burnstein, Kerry L., and Zhang, Fangliang
- Published
- 2019
- Full Text
- View/download PDF
42. Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner
- Author
-
Kato, Manabu, Placencio-Hickok, Veronica R., Madhav, Anisha, Haldar, Subhash, Tripathi, Manisha, Billet, Sandrine, Mishra, Rajeev, Smith, Bethany, Rohena-Rivera, Krizia, Agarwal, Priyanka, Duong, Frank, Angara, Bryan, Hickok, David, Liu, Zhenqiu, and Bhowmick, Neil A.
- Published
- 2019
- Full Text
- View/download PDF
43. Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche
- Author
-
Shahriari, K, Shen, F, Worrede-Mahdi, A, Liu, Q, Gong, Y, Garcia, F U, and Fatatis, A
- Published
- 2017
- Full Text
- View/download PDF
44. The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells
- Author
-
Ma, S Q, Cao, B R, Zhang, H, Luo, L P, Ren, Y, Hu, T, and Chen, C M
- Published
- 2017
- Full Text
- View/download PDF
45. The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related
- Author
-
Rice, M A, Ishteiwy, R A, Magani, F, Udayakumar, T, Reiner, T, Yates, T J, Miller, P, Perez-Stable, C, Rai, P, Verdun, R, Dykxhoorn, D M, and Burnstein, K L
- Published
- 2016
- Full Text
- View/download PDF
46. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis
- Author
-
Lee, S H, Luong, R, Johnson, D T, Cunha, G R, Rivina, L, Gonzalgo, M L, and Sun, Z
- Published
- 2016
- Full Text
- View/download PDF
47. Role of diet in prostate cancer: the epigenetic link
- Author
-
Labbé, D P, Zadra, G, Ebot, E M, Mucci, L A, Kantoff, P W, Loda, M, and Brown, M
- Published
- 2015
- Full Text
- View/download PDF
48. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma
- Author
-
Pardali, E, van der Schaft, D W J, Wiercinska, E, Gorter, A, Hogendoorn, P C W, Griffioen, A W, and ten Dijke, P
- Published
- 2011
- Full Text
- View/download PDF
49. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer
- Author
-
Yu, J, Cao, Q, Yu, J, Wu, L, Dallol, A, Li, J, Chen, G, Grasso, C, Cao, X, Lonigro, R J, Varambally, S, Mehra, R, Palanisamy, N, Wu, J Y, Latif, F, and Chinnaiyan, A M
- Published
- 2010
- Full Text
- View/download PDF
50. The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells
- Author
-
Russell, M R, Jamieson, W L, Dolloff, N G, and Fatatis, A
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.